Santen Pharmaceutical (China) Co., LTD

Enterprise Pain:

Santen Pharmaceutical’s internal management is strict, and the original manual excel manufacturing can no longer meet the needs. There is an urgent need for an information system to improve internal management issues and improve the level of collation and collaboration.

Solution:

The customs system of Guanheng integrates complete goods and customs declaration commodity merging relationship files and data docking with ERP original documents (such as orders, packing lists, notices, etc.) and finally completes the visualization and intelligent declaration document production process, to free the customs staff from the trivial manual work mode and frequent business communication process, so that they can devote more energy to the enterprise’s own customs information construction.

Project Achievement:

1. Customs data information management, permanent storage can be downloaded and viewed at any time, can respond to customs data inspection at any time;

2. Data sharing of various departments of the enterprise completes internal and external control and avoids enterprise trade management risks;

3. The work report of each department is clear at a glance, and the leaders can understand the situation in time to meet the internal management requirements.

Brief Introduction:

Santen was founded in 1890 and has a history of 130 years. As a company focused on ophthalmology, Santen is mainly engaged in the research and development, marketing and sales of drugs, over-the-counter products and medical devices. Its products have now covered patients in more than 60 countries/regions.

Santen Pharmaceutical (China) Co., Ltd. was established on September 21, 2005. Its registered place is located at No. 169, Tinglan Lane, Suzhou Industrial Park. The legal representative is YAMADA TAKAYUKI.

Santen has been engaged in the research and development of new ophthalmic drugs for a long time, and has 29 subsidiaries around the world. In addition to Japan, it also has development, research, production, and sales branches in Europe, the United States, and Asian countries. At the same time, development and sales activities are being carried out in many countries around the world. The towering ophthalmic prescription drug market share ranks first in Japan and South Korea, with an annual production of about 400 million bottles of eye drops. The products are exported to more than 60 countries and provide ophthalmic solutions to more than 30 million ophthalmic patients worldwide each year.